Table 2.

Appellation, target, and clinical application of BCL-2 inhibitors.

Drug names	Target	Clinical application
Oblimersen (154)	mRNA of BCL-2	Myeloma (stage III)
Obatoclax (155)	BCL-2	CCL
	MCL-1	AML
	BCL-XL	NSCLC
	BFL-1	HL (stage II)
	BCL-W	SCLC (stage II)
Navitoclax (156)	BCL-2	Myeloma (stage I)
		CLL (stage I~III)
		NHL (stage I~III)
		AML (stage I~II)